Compare FFBC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFBC | DNLI |
|---|---|---|
| Founded | 1863 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2004 | 2017 |
| Metric | FFBC | DNLI |
|---|---|---|
| Price | $30.80 | $20.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $30.71 | ★ $34.33 |
| AVG Volume (30 Days) | 709.7K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | ★ 10.83 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.67 | N/A |
| Revenue Next Year | $4.58 | $408.85 |
| P/E Ratio | $11.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.63 | $12.58 |
| 52 Week High | $31.38 | $23.77 |
| Indicator | FFBC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 68.26 | 49.30 |
| Support Level | $23.31 | $18.86 |
| Resistance Level | $31.38 | $20.71 |
| Average True Range (ATR) | 0.65 | 0.85 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 79.38 | 35.74 |
First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and noninterest-bearing accounts, time deposits and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.